AstraZeneca’s chief executive Pascal Soriot believes its COVID-19 vaccine could still gain approval by the end of 2020, despite the pause it announced on its clinical trials this week.
All studies of AZN1222 have been suspended following a serious adverse event in a single participant in a UK-based Phase...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
